Follow

AcouSort AB

Nasdaq First North GM Stockholm (Sweden)

AcouSort is a is a biotech company which provides solutions for automated sample preparations involving biological cells or other organelles. Its technology is based on using ultrasound to isolate, separate or trap microscopic particles such as blood cells, bacteria or extracellular vesicles in microfluidic channels.
Go to market

Sector:
HEALTH CARE
>
Biotechnology
Healthcare
Media
Exercise
Price
25.00 SEK
Exercise period(s)
01 Dec - 09 Dec 2022
Instruments & Events
The shares and options available for this company. Including past events like IPOs, direct listings and exercise periods.

NB! Information about past events and all documents are available for signed in users who have bought those events.

Type
Ticker
ISIN
Market
SHARE
ACOU
SE0009189608
Nasdaq First North GM Stockholm
Sweden (SE)
Details of share in AcouSort AB with ticker ACOU
Status
Active
Amount of instruments
11 316 245
Currency
SEK
First trading date
09 Jan 2016
Rights issue
Sign in to buy
Directed issue
Sign in to buy
Market move
Sign in to buy
Rights issue
Sign in to buy
Type
Ticker
ISIN
Market
OPTION
ACOU TO1
SE0016830194
Nasdaq First North GM Stockholm
Sweden (SE)
Details of option in AcouSort AB with ticker ACOU TO1
Status
Active
Amount of instruments
1 886 040
Currency
SEK
Trading period
08 Nov 2021 - 07 Dec 2022
Terms
Three (3) warrants entitles the holder to subscribe for one (1) new share for SEK 25.0 during the period December 1, 2022 - December 9, 2022.
Update (02.11.2021): First trading day for warrants TO1 is November 8, 2021.
Exercise
Sign in to buy
People
Torsten Freltoft
CEO
Martin Olin
Chairman of the board
Kristian Enkvist
Board member
Stefan Scheding
Board member
Thomas Laurell
Board member
Company Details
Sector
HEALTH CARE

Address
Medicon Village
Zip code
223 81
City/district
Lund
Country
Sweden (SE)
Registration number
556824-1037
LEI code
549300PTSH3X6GMBFS32
First trade date
09 Jan 2017
Registration date
08 Nov 2010
Short name
ACOU

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More